Last updated: 2026-11-14 11:01:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
ABBVIE INC. (ABBV) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NYSE. The stock is currently priced at $295.06, with a market capitalization of $520.47B and a P/E ratio of 50.38. Over the past 52 weeks, its price has ranged from $190.75 to $302.93. This page covers its latest market performance, valuation, price trends and company information.
$520.47B | |
$296.58 | |
$297.42 | |
$293.70 | |
$294.45 | |
2.23M | |
4.80M | |
50.38 | |
$302.93 | |
$190.75 | |
2.33% | |
12-31 |
ABBVIE INC. (ABBV) last closed at $295.06 as of 2026-11-14 00:57:36, up 0.15% ($0.43) from the previous close of $294.45.
During the latest regular trading session, ABBV traded between $293.70 and $297.42, with a volume of 2.23M shares. The closing price was near the middle and near the upper end of its 52-week range.
Over the past seven days, ABBVIE INC. (ABBV) moved from $288.24 to $295.06, representing a gain of 2.37% ($6.82).
The stock traded between $281.07 and $302.93 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 4.82 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 93.0%
ABBV is currently trading at $295.06, placing it 93.0% of the way from its 52-week low of $190.75 to its 52-week high of $302.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio, while the 2026 acquisition of Apogee adds to AbbVie's immunology depth.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 57,000 |
| CEO | Robert A. Michael |
| Founded | 2012 |
| Exchange | NYSE |
| Company Website |
View the latest dividend and stock split events for ABBVIE INC.
Dividend | |
|---|---|
| Ex-Dividend Date | Jan 15, 2027 |
| Payment Date | Feb 16, 2027 |
| Dividend Per Share | $1.82 |
Latest news related to ABBVIE INC. and ABBV stock.
As tech stocks struggle post-election, investors are rotating into defensive sectors like healthcare. The State Street Healthcare Select Sector SPDR ETF (XLV) has gained 23% in 2026, outperforming the S&P 500's 11% return. Healthcare's inelastic demand makes it attractive during market volatility, though investors should consider dollar-cost averaging given the recent run-up.
With the S&P 500 trading at valuations similar to 1999 (driven by AI hype instead of the dot-com boom), the article recommends three dividend stocks positioned to weather potential market corrections: AbbVie for healthcare stability, Enterprise Products Partners for consistent cash flow, and JPMorgan Chase to benefit from rising interest rates.
DelveInsight released a comprehensive competitive landscape report on BCMA-targeted therapies, analyzing 100+ pipeline drugs across 80+ companies. The report highlights recent clinical advances including Pfizer's positive Phase III results for ELREXFIO, AbbVie's BLA submission for etentamig, and Gilead's $7.8 billion acquisition of Arcellx to gain control of anito-cel. Key challenges include treatment resistance, relapse, and manufacturing complexity, while the pipeline focuses on improving durability, safety, and accessibility through next-generation approaches.
AbbVie reported strong Q3 2026 results with immunology revenues rising 16.6% to $9.2 billion, driven by blockbuster drugs Skyrizi (up 22.9%) and Rinvoq (up 24.3%), offsetting Humira's 30.6% decline due to biosimilar competition. The company raised 2026 sales forecasts for both drugs, expecting combined growth exceeding 20%, with new indications in inflammatory bowel disease and dermatology providing additional growth opportunities.
Zacks equity research analysts published analysis on five stocks. NVIDIA faces China restrictions and competition but benefits from AI infrastructure demand. Walmart outperforms its industry with strong omnichannel operations but faces cost pressures. AbbVie offsets Humira's decline with strong growth from newer drugs. Pioneer Bancorp outperforms its industry with solid fundamentals. Aspira significantly underperforms its industry with liquidity constraints and execution risks.
Eligible investors can buy real shares of ABBVIE INC. (ABBV) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Browse other US stocks in the same sector as ABBVIE INC.
See US stocks with the highest market capitalization
Discover today's most actively traded US stocks
Browse today's leading gainers in the US stock market
Explore the cryptocurrencies with the highest market capitalization
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ABBV, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ABBV shares and USD.
ABBV Shares to USD
1.00 ABBV shares = 295.061 USD
Calculations are estimates based on the latest available price and are for reference only.
